Genome & Co.
Biotechnology company (founded 2015) focused on discovery and development of microbiome-based therapeutics and novel biologics. Operates a platform for microbiome and multi-omics–driven target discovery and maintains a clinical-stage pipeline including microbiome therapeutic candidates and antibody biologics. Engages in clinical collaborations, manufacturing partnerships and licensing for development and commercialization.
Industries
Nr. of Employees
small (1-50)
Genome & Co.
Products
GEN-001
Clinical-stage microbiome-derived therapeutic candidate developed for immuno-oncology combination studies.
SB-121
Microbiome-derived therapeutic candidate developed for neurological indications; reported Phase I clinical completion.
GENA-104
Antibody biologic candidate targeting a novel immune-oncology target identified by the company's discovery platform; subject to manufacturing and process-development agreements.
GENA-120
Biologics candidate listed in company pipeline.
GENA-121
Biologics candidate listed in company pipeline.
GENA-122
Biologics candidate listed in company pipeline.
GEN-001
Clinical-stage microbiome-derived therapeutic candidate developed for immuno-oncology combination studies.
SB-121
Microbiome-derived therapeutic candidate developed for neurological indications; reported Phase I clinical completion.
GENA-104
Antibody biologic candidate targeting a novel immune-oncology target identified by the company's discovery platform; subject to manufacturing and process-development agreements.
GENA-120
Biologics candidate listed in company pipeline.
GENA-121
Biologics candidate listed in company pipeline.
GENA-122
Biologics candidate listed in company pipeline.
Expertise Areas
- Microbiome-based therapeutic discovery
- Live biotherapeutic product development
- Multi-omics–driven target discovery
- Monoclonal antibody and biologics discovery
Key Technologies
- Microbiome therapeutics
- Live-microorganism formulation
- Multi-omics data integration
- Monoclonal antibody discovery
News & Updates
Investor relations book and analyst materials available for download from the IR data room.
Company notice reporting completion of a Phase I clinical study for a microbiome therapeutic candidate (SB-121).
Notice regarding progression of a microbiome immuno-oncology candidate into Phase 1b and Phase 2 combination studies with external oncology agents.
Contract for production and process development with a contract development and manufacturing organization for an antibody biologic candidate.
Joint research agreement and/or technology transfer related to ADC development with an external oncology-focused company.
Series and financing rounds and investments reported across 2016–2023, including Series B/C and later rounds and strategic investments in affiliated companies.
Investor relations book and analyst materials available for download from the IR data room.
Company notice reporting completion of a Phase I clinical study for a microbiome therapeutic candidate (SB-121).
Notice regarding progression of a microbiome immuno-oncology candidate into Phase 1b and Phase 2 combination studies with external oncology agents.
Contract for production and process development with a contract development and manufacturing organization for an antibody biologic candidate.
Joint research agreement and/or technology transfer related to ADC development with an external oncology-focused company.
Series and financing rounds and investments reported across 2016–2023, including Series B/C and later rounds and strategic investments in affiliated companies.